De Hert Stefan G, Lorsomradee Suraphong, Cromheecke Stefanie, Van der Linden Philippe J
Department of Anesthesiology, University of Antwerp, University Hospital Antwerp, Belgium.
Anesth Analg. 2007 Apr;104(4):766-73. doi: 10.1213/01.ane.0000256863.92050.d3.
Patients with poor left ventricular function often require inotropic drug support immediately after cardiopulmonary bypass. Levosimendan improves cardiac function by a novel mechanism of action compared to currently available drugs. We hypothesized that, in patients with severely compromised ventricular function, the use of levosimendan would be associated with better postoperative cardiac function than with inotropic drugs that increase myocardial oxygen consumption.
Thirty patients with a preoperative ejection fraction < or =30% scheduled for elective cardiac surgery with cardiopulmonary bypass were randomized to two different inotropic protocols: milrinone 0.5 microg [corrected] x kg(-1) x min(-1) or levosimendan 0.1 microg [corrected] x kg(-1) x min(-1), started immediately after the release of the aortic crossclamp. The treatment was masked to the observers. All patients received dobutamine 5 microg [corrected] x kg(-1) x min(-1).
Stroke volume was similar between groups initially after surgery, but it declined 12 h after surgery in the milrinone group but not in the levosimendan group (P < 0.05 between groups) despite similar filling pressures. Total dose, duration of inotropic drug administration and norepinephrine dose were lower in the levosimendan group than in the milrinone group (P < 0.05). The duration of tracheal intubation was shorter in the former group compared with the milrinone group (P = 0008). Three patients in the milrinone group but none in the levosimendan group died within 30 days of surgery.
In cardiac surgery patients with a low preoperative ejection fraction, stroke volume was better maintained with the combination of dobutamine with levosimendan than with the combination of dobutamine with milrinone.
左心室功能较差的患者在体外循环后常需要立即使用正性肌力药物支持。与现有药物相比,左西孟旦通过一种新的作用机制改善心脏功能。我们假设,在心室功能严重受损的患者中,使用左西孟旦比使用增加心肌氧消耗的正性肌力药物能使术后心脏功能更好。
30例计划行择期体外循环心脏手术、术前射血分数≤30%的患者被随机分为两种不同的正性肌力方案:米力农0.5微克/千克/分钟或左西孟旦0.1微克/千克/分钟,在主动脉阻断钳松开后立即开始使用。观察者对治疗方案不知情。所有患者均接受多巴酚丁胺5微克/千克/分钟。
术后最初两组的每搏量相似,但尽管充盈压相似,米力农组术后12小时每搏量下降,而左西孟旦组未下降(两组间P<0.05)。左西孟旦组的正性肌力药物总剂量、给药持续时间和去甲肾上腺素剂量均低于米力农组(P<0.05)。与米力农组相比,左西孟旦组气管插管时间更短(P = 0.008)。米力农组有3例患者在术后30天内死亡,而左西孟旦组无死亡病例。
在术前射血分数较低的心脏手术患者中,多巴酚丁胺与左西孟旦联合使用比多巴酚丁胺与米力农联合使用能更好地维持每搏量。